Stoke Therapeutics, Inc. STOK Other comprehensive income (loss)
Other comprehensive income (loss) at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossNetOfTax.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s other comprehensive income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s other comprehensive income (loss)?
- Stoke Therapeutics, Inc. (STOK) reported other comprehensive income (loss) of -$658K in Q1 2026.
- How has Stoke Therapeutics, Inc.'s other comprehensive income (loss) changed year-over-year?
- Stoke Therapeutics, Inc.'s other comprehensive income (loss) decreased by 1500.0% year-over-year, from $47K to -$658K.
- What is the long-term trend for Stoke Therapeutics, Inc.'s other comprehensive income (loss)?
- Over 3 years (2021 to 2025), Stoke Therapeutics, Inc.'s other comprehensive income (loss) has grown at a 60.5% compound annual growth rate (CAGR), from -$168K to $694K.
- What does other comprehensive income (loss) mean?
- This metric captures all non-owner changes in equity that are excluded from the traditional net income calculation. It includes items such as unrealized gains or losses on securities and foreign currency translation adjustments. It provides a broader view of the company's financial performance by accounting for volatility that does not stem from day-to-day operations.